These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
248 related articles for article (PubMed ID: 26143754)
1. Downregulation of miR-363 increases drug resistance in cisplatin-treated HepG2 by dysregulating Mcl-1. Ou Y; Zhai D; Wu N; Li X Gene; 2015 Nov; 572(1):116-122. PubMed ID: 26143754 [TBL] [Abstract][Full Text] [Related]
2. Upregulated miR-182 increases drug resistance in cisplatin-treated HCC cell by regulating TP53INP1. Qin J; Luo M; Qian H; Chen W Gene; 2014 Apr; 538(2):342-7. PubMed ID: 24447717 [TBL] [Abstract][Full Text] [Related]
3. miR-193b acts as a cisplatin sensitizer via the caspase-3-dependent pathway in HCC chemotherapy. Yin W; Nie Y; Zhang Z; Xie L; He X Oncol Rep; 2015 Jul; 34(1):368-74. PubMed ID: 25997995 [TBL] [Abstract][Full Text] [Related]
4. MicroRNA-101 sensitizes hepatocellular carcinoma cells to doxorubicin-induced apoptosis via targeting Mcl-1. He H; Tian W; Chen H; Deng Y Mol Med Rep; 2016 Feb; 13(2):1923-9. PubMed ID: 26718267 [TBL] [Abstract][Full Text] [Related]
5. MiR-363 sensitizes cisplatin-induced apoptosis targeting in Mcl-1 in breast cancer. Zhang R; Li Y; Dong X; Peng L; Nie X Med Oncol; 2014 Dec; 31(12):347. PubMed ID: 25416050 [TBL] [Abstract][Full Text] [Related]
6. Mcl-1 Is a Novel Target of miR-26b That Is Associated with the Apoptosis Induced by TRAIL in HCC Cells. Jiang C; Long J; Liu B; Xie X; Kuang M Biomed Res Int; 2015; 2015():572738. PubMed ID: 26078955 [TBL] [Abstract][Full Text] [Related]
7. MiR-141 Activates Nrf2-Dependent Antioxidant Pathway via Down-Regulating the Expression of Keap1 Conferring the Resistance of Hepatocellular Carcinoma Cells to 5-Fluorouracil. Shi L; Wu L; Chen Z; Yang J; Chen X; Yu F; Zheng F; Lin X Cell Physiol Biochem; 2015; 35(6):2333-48. PubMed ID: 25896253 [TBL] [Abstract][Full Text] [Related]
8. Cisplatin-induced downregulation of miR-199a-5p increases drug resistance by activating autophagy in HCC cell. Xu N; Zhang J; Shen C; Luo Y; Xia L; Xue F; Xia Q Biochem Biophys Res Commun; 2012 Jul; 423(4):826-31. PubMed ID: 22713463 [TBL] [Abstract][Full Text] [Related]
9. Restoration of miR-193b sensitizes Hepatitis B virus-associated hepatocellular carcinoma to sorafenib. Mao K; Zhang J; He C; Xu K; Liu J; Sun J; Wu G; Tan C; Zeng Y; Wang J; Xiao Z Cancer Lett; 2014 Oct; 352(2):245-52. PubMed ID: 25034398 [TBL] [Abstract][Full Text] [Related]
10. MiR-34a overexpression enhances the inhibitory effect of doxorubicin on HepG2 cells. Zheng SZ; Sun P; Wang JP; Liu Y; Gong W; Liu J World J Gastroenterol; 2019 Jun; 25(22):2752-2762. PubMed ID: 31235998 [TBL] [Abstract][Full Text] [Related]
11. Identification of mTOR as a primary resistance factor of the IAP antagonist AT406 in hepatocellular carcinoma cells. Zhen MC; Wang FQ; Wu SF; Zhao YL; Liu PG; Yin ZY Oncotarget; 2017 Feb; 8(6):9466-9475. PubMed ID: 28036295 [TBL] [Abstract][Full Text] [Related]
12. Inhibition of the JNK signaling pathway increases sensitivity of hepatocellular carcinoma cells to cisplatin by down-regulating expression of P-glycoprotein. Liu XY; Liu SP; Jiang J; Zhang X; Zhang T Eur Rev Med Pharmacol Sci; 2016; 20(6):1098-108. PubMed ID: 27049263 [TBL] [Abstract][Full Text] [Related]
13. microRNA-539 suppresses tumor growth and tumorigenesis and overcomes arsenic trioxide resistance in hepatocellular carcinoma. Zhu C; Zhou R; Zhou Q; Chang Y; Jiang M Life Sci; 2016 Dec; 166():34-40. PubMed ID: 27717846 [TBL] [Abstract][Full Text] [Related]
14. Inhibition of miR-15a-5p Promotes the Chemoresistance to Pirarubicin in Hepatocellular Carcinoma via Targeting eIF4E. Zhang Y; Tie Q; Bao Z; Shao Z; Zhang L Comput Math Methods Med; 2021; 2021():6468405. PubMed ID: 34812269 [TBL] [Abstract][Full Text] [Related]
15. Astemizole promotes the anti-tumor effect of vitamin D through inhibiting miR-125a-5p-meidated regulation of VDR in HCC. Xu J; Wang Y; Zhang Y; Dang S; He S Biomed Pharmacother; 2018 Nov; 107():1682-1691. PubMed ID: 30257386 [TBL] [Abstract][Full Text] [Related]
16. miR-340 reverses cisplatin resistance of hepatocellular carcinoma cell lines by targeting Nrf2-dependent antioxidant pathway. Shi L; Chen ZG; Wu LL; Zheng JJ; Yang JR; Chen XF; Chen ZQ; Liu CL; Chi SY; Zheng JY; Huang HX; Lin XY; Zheng F Asian Pac J Cancer Prev; 2014; 15(23):10439-44. PubMed ID: 25556489 [TBL] [Abstract][Full Text] [Related]
18. MiR-27a-3p enhances the cisplatin sensitivity in hepatocellular carcinoma cells through inhibiting PI3K/Akt pathway. Yang Y; Yang Z; Zhang R; Jia C; Mao R; Mahati S; Zhang Y; Wu G; Sun YN; Jia XY; Aimudula A; Zhang H; Bao Y Biosci Rep; 2021 Dec; 41(12):. PubMed ID: 34096570 [TBL] [Abstract][Full Text] [Related]
19. miR-181a induces sorafenib resistance of hepatocellular carcinoma cells through downregulation of RASSF1 expression. Azumi J; Tsubota T; Sakabe T; Shiota G Cancer Sci; 2016 Sep; 107(9):1256-62. PubMed ID: 27384977 [TBL] [Abstract][Full Text] [Related]
20. MiR-519d impedes cisplatin-resistance in breast cancer stem cells by down-regulating the expression of MCL-1. Xie Q; Wang S; Zhao Y; Zhang Z; Qin C; Yang X Oncotarget; 2017 Mar; 8(13):22003-22013. PubMed ID: 28423543 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]